title: Clinical potential of aclidinium bromide in chronic obstructive pulmonary disease.
abstract: Three long-acting muscarinic antagonists (LAMAs) are now available in Europe, providing clinicians and patients with a choice of interventions, which is important in COPD, which is clinically a heterogeneous disease. The first LAMA, tiotropium, has been widely used over the last decade as a once-daily maintenance therapy in stable COPD to improve patients' health-related quality of life and to reduce the risk of exacerbations. Administered via the HandiHaler(®) device, it is safe and well tolerated. Another new once-daily LAMA, glycopyrronium, has also been shown to improve health status and reduce exacerbations, and is well tolerated. The subject of this review is a third LAMA, aclidinium bromide, which was approved as a twice-daily maintenance bronchodilator treatment. In the pivotal Phase III clinical trials, patients receiving aclidinium achieved significantly greater improvements in lung function, reductions in breathlessness, and improvements in health status compared with placebo, for up to 24 weeks. In continuation studies, these improvements were sustained for up to 52 weeks. Pooled data showed exacerbation frequency was significantly reduced with aclidinium versus placebo. Preclinical and pharmacological studies demonstrating low systemic bioavailability and a low propensity to induce cardiac arrhythmias were translated into a favorable tolerability profile in the clinical trial program - the adverse event profile of aclidinium was similar to placebo, with a low incidence of anticholinergic and cardiac adverse events. While additional studies are needed to evaluate its full clinical potential, aclidinium is an important part of this recent expansion of LAMA therapeutic options, providing clinicians and patients with an effective and well-tolerated COPD treatment.
authors.affiliation: Institute for Infection and Immunity, Faculty of Respiratory Medicine, St George's, University of London, London, UK.
authors.forename: Paul W
authors.initials: PW
authors.lastname: Jones
mesh_terms: D001993:Bronchodilator Agents / Q000009:adverse effects / Q000627:therapeutic use*; D018450:Disease Progression; D006801:Humans; D008168:Lung / Q000187:drug effects* / Q000503:physiopathology; D018727:Muscarinic Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D029424:Pulmonary Disease, Chronic Obstructive / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D020127:Recovery of Function; D012720:Severity of Illness Index; D013997:Time Factors; D016896:Treatment Outcome; D014326:Tropanes / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D001993:Bronchodilator Agents; D018727:Muscarinic Antagonists; D014326:Tropanes; C542859:aclidinium bromide
keywords: aclidinium bromide; anticholinergic; chronic obstructive pulmonary disease; long-acting muscarinic antagonist; multidose dry powder inhaler
references.citation: Eur Respir J. 2012 Oct;40(4):830-6
references.pmid: 22441743
references.citation: COPD. 2013 Aug;10(4):500-10
references.pmid: 23679347
references.citation: Cochrane Database Syst Rev. 2014;7:CD009285
references.pmid: 25046211
references.citation: Pulm Pharmacol Ther. 2010 Feb;23(1):15-21
references.pmid: 19683590
references.citation: Int J Chron Obstruct Pulmon Dis. 2012;7:673-8
references.pmid: 23055716
references.citation: J Pharmacol Exp Ther. 2009 Nov;331(2):740-51
references.pmid: 19710368
references.citation: Expert Opin Drug Deliv. 2013 Aug;10(8):1023-31
references.pmid: 23745954
references.citation: COPD. 2013 Aug;10(4):511-22
references.pmid: 23819698
references.citation: Pulm Pharmacol Ther. 2012 Apr;25(2):193-9
references.pmid: 22366196
references.citation: Respir Med. 2011 Mar;105(3):337-42
references.pmid: 21144724
references.citation: COPD. 2005 Mar;2(1):111-24
references.pmid: 17136971
references.citation: Clin Ther. 2010 Sep;32(10):1798-812
references.pmid: 21194604
references.citation: Int J Chron Obstruct Pulmon Dis. 2012;7:503-13
references.pmid: 22973092
references.citation: Respir Res. 2011;12:55
references.pmid: 21518460
references.citation: Int J Clin Pharmacol Ther. 2012 Feb;50(2):118-28
references.pmid: 22257577
references.citation: Cochrane Database Syst Rev. 2014;9:CD010509
references.pmid: 25234126
references.citation: Respir Med. 2013 Dec;107(12):1957-65
references.pmid: 23916502
references.citation: COPD. 2012 Apr;9(2):90-101
references.pmid: 22320148
references.citation: Pulm Pharmacol Ther. 2010 Oct;23(5):438-44
references.pmid: 20416390
references.citation: Clin Drug Investig. 2013 Dec;33(12):893-904
references.pmid: 24085591
references.citation: Thorax. 2013 Jan;68(1):48-56
references.pmid: 23042705
references.citation: BMJ. 2011;342:d3215
references.pmid: 21672999
references.citation: BMJ Open. 2012 May 22;2(3):null
references.pmid: 22619266
references.citation: JAMA. 2008 Sep 24;300(12):1439-50
references.pmid: 18812535
references.citation: N Engl J Med. 2013 Oct 17;369(16):1491-501
references.pmid: 23992515
references.citation: Int J Clin Pharmacol Ther. 2012 Jun;50(6):403-12
references.pmid: 22541745
references.citation: Pulm Pharmacol Ther. 2012 Jun;25(3):248-53
references.pmid: 22497752
references.citation: N Engl J Med. 2008 Oct 9;359(15):1543-54
references.pmid: 18836213
references.citation: Eur Respir J. 2012 Nov;40(5):1106-14
references.pmid: 23060624
references.citation: Chest. 2012 Jan;141(1):81-6
references.pmid: 21799028
references.citation: J Clin Pharmacol. 2009 Oct;49(10):1239-46
references.pmid: 19592595
references.citation: Respir Med. 2011 Jun;105(6):930-8
references.pmid: 21367593
references.citation: COPD. 2005 Mar;2(1):99-103
references.pmid: 17136969
references.citation: Respir Med. 2010 Jun;104(6):865-72
references.pmid: 20044242
references.citation: Chest. 2012 Mar;141(3):745-52
references.pmid: 21903737
references.citation: Respir Res. 2011;12:156
references.pmid: 22151296
references.citation: Am J Respir Crit Care Med. 2011 Feb 1;183(3):323-9
references.pmid: 20813886
references.citation: Respir Med. 1991 Sep;85 Suppl B:25-31; discussion 33-7
references.pmid: 1759018
references.citation: J Clin Pharmacol. 2011 Jun;51(6):923-32
references.pmid: 20959525
references.citation: Respir Med. 2010 Oct;104(10):1482-9
references.pmid: 20541381
references.citation: Eur Respir J. 2013 Sep;42(3):606-15
references.pmid: 23520322